查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1467598

2024-2032 年按抗體類型、藥物類型（貝伐單抗、利妥昔單抗、曲妥珠單抗、西妥昔單抗、帕尼單抗等）、應用、最終用戶和地區分類的癌症單株抗體市場報告

Cancer Monoclonal Antibodies Market Report by Antibody Type, Medication Type (Bevacizumab, Rituximab, Trastuzumab, Cetuximab, Panitumumab, and Others), Application, End-User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 136 Pages | 商品交期: 2-3個工作天內

價格

2023年，全球癌症IMARC Group抗體市場規模達466億美元。

癌症單株抗體是指實驗室生成的分子，經過改造後可模仿免疫系統對癌細胞的攻擊。它可以與癌細胞表面的抗原結合併標記它們，從而觸發細胞膜的破壞、阻止細胞生長和免疫系統抑制劑。它還可以直接向癌細胞提供治療輻射以中和或消滅它們。一些最常用的單株抗體包括鼠源抗體、嵌合抗體和人源化抗體，用於治療血液、肝癌、腦癌和乳癌。

全球癌症盛行率不斷上升是推動市場成長的關鍵因素之一。與傳統使用的非標靶療法（例如化療）相比，單株抗體對患者身體的副作用減少，也可用於治療自體免疫疾病和發炎性疾病。此外，醫生和腫瘤學家廣泛採用具有成本效益的生物相似藥單株抗體也促進了市場成長。隨著基因定序和目標基因選擇的技術進步，這些抗體可以被修改為具有與藥物相似的特性。它們具有相同的功效，但價格比原廠藥更低，這有助於提高治療的成本效益，從而促進全球對該產品的需求不斷增加。其他因素，包括對個人化藥物的日益偏好、廣泛的研發 (R&D) 活動以及醫療保健基礎設施的顯著改善，預計將進一步推動市場發展。

本報告回答的關鍵問題：

  • 迄今為止，全球癌症單株抗體市場表現如何，未來幾年將如何表現？
  • 主要區域市場有哪些？
  • COVID-19對全球癌症單株抗體市場有何影響？
  • 根據抗體類型的市場分類是怎樣的？
  • 根據藥物類型分類的市場是怎麼樣的？
  • 基於應用程式的市場區隔是什麼？
  • 基於最終用戶的市場區隔是什麼？
  • 產業價值鏈的各個階段是什麼？
  • 該行業的關鍵促進因素和挑戰是什麼？
  • 全球癌症單株抗體市場的結構如何？
  • 產業競爭程度如何？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球癌症單株抗體市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：按抗體類型

  • 鼠抗體
    • 市場走向
    • 市場預測
  • 嵌合抗體
    • 市場走向
    • 市場預測
  • 人源化抗體
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 7 章：市場區隔：按藥物類型

  • 貝伐珠單抗（阿瓦斯汀）
    • 市場走向
    • 市場預測
  • 利妥昔單抗（Rituxan）
    • 市場走向
    • 市場預測
  • 曲妥珠單抗（赫賽汀）
    • 市場走向
    • 市場預測
  • 西妥昔單抗（愛必妥）
    • 市場走向
    • 市場預測
  • 帕尼單抗（Vectibix）
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 8 章：市場區隔：按應用

  • 乳癌
    • 市場走向
    • 市場預測
  • 血癌
    • 市場走向
    • 市場預測
  • 肝癌
    • 市場走向
    • 市場預測
  • 腦癌
    • 市場走向
    • 市場預測
  • 大腸直腸癌
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按最終用戶

  • 醫院和診所
    • 市場走向
    • 市場預測
  • 藥局
    • 市場走向
    • 市場預測
  • 研究實驗室
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 10 章：市場區隔：按地區

  • 北美洲
    • 美國
      • 市場走向
      • 市場預測
    • 加拿大
      • 市場走向
      • 市場預測
  • 亞太地區
    • 中國
      • 市場走向
      • 市場預測
    • 日本
      • 市場走向
      • 市場預測
    • 印度
      • 市場走向
      • 市場預測
    • 韓國
      • 市場走向
      • 市場預測
    • 澳洲
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 歐洲
    • 德國
      • 市場走向
      • 市場預測
    • 法國
      • 市場走向
      • 市場預測
    • 英國
      • 市場走向
      • 市場預測
    • 義大利
      • 市場走向
      • 市場預測
    • 西班牙
      • 市場走向
      • 市場預測
    • 俄羅斯
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場走向
      • 市場預測
    • 墨西哥
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 11 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 12 章：價值鏈分析

第 13 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Amgen Inc.
    • Roche Holding AG
    • AbbVie Inc.
    • Johnson & Johnson
    • Eli Lilly and Company
    • Merck & Co. Inc.
    • Genmab A/S
    • GlaxoSmithKline Plc.
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Spectrum Pharmaceuticals Inc.
    • Seattle Genetics Inc.
    • Pfizer Inc.
Product Code: SR112024A1955

The global cancer monoclonal antibodies market size reached US$ 46.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 64.6 Billion by 2032, exhibiting a growth rate (CAGR) of 3.6% during 2024-2032.

A cancer monoclonal antibody refers to a laboratory-generated molecule that is engineered to mimic the immune system's attack on cancer cells. It can bind to antigens present on the surface of cancer cells and flag them to trigger the destruction of cell membranes, block cell growth and immune system inhibitors. It can also deliver treatment radiations directly to the cancer cells to neutralize or destroy them. Some of the most commonly used monoclonal antibodies include murine, chimeric and humanized antibodies that are employed in the treatment of cancer in the blood, liver, brain and breast.

The increasing prevalence of cancer across the globe is one of the key factors driving the growth of the market. In comparison to traditionally used non-targeted therapies, such as chemotherapy, monoclonal antibodies have reduced side-effects on the patient's body and can also be used for the treatment of autoimmune and inflammatory diseases. Furthermore, widespread adoption of cost-efficient biosimilar monoclonal antibodies by medical practitioners and oncologists is also providing a boost to the market growth. With technological advancements in gene sequencing and target gene selection, these antibodies can be modified to have similar properties to that of a pharmaceutical drug. They have the same efficiency but are available at reduced prices than the original medicine, which aids in enhancing the cost-efficiency of the treatment, thereby contributing to the increasing demand for the product across the globe. Other factors, including rising preference for personalized medicines, extensive research and development (R&D) activities and significant improvements in the healthcare infrastructure, are projected to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global cancer monoclonal antibodies market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on antibody type, medication type, end-user and application.

Breakup by Antibody Type:

Murine Antibodies

Chimeric Antibodies

Humanized Antibodies

Others

Breakup by Medication Type:

Bevacizumab (Avastin)

Rituximab (Rituxan)

Trastuzumab (Herceptin)

Cetuximab (Erbitux)

Panitumumab (Vectibix)

Others

Breakup by Application:

Breast Cancer

Blood Cancer

Liver Cancer

Brain Cancer

Colorectal Cancer

Others

Breakup by End-User:

Hospitals and Clinics

Pharmacies

Research Laboratories

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Genmab A/S, GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Seattle Genetics Inc., Spectrum Pharmaceuticals Inc., etc.

Key Questions Answered in This Report:

  • How has the global cancer monoclonal antibodies market performed so far and how will it perform in the coming years?
  • What are the key regional markets?
  • What has been the impact of COVID-19 on the global cancer monoclonal antibodies market?
  • What is the breakup of the market based on the antibody type?
  • What is the breakup of the market based on the medication type?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the end-user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global cancer monoclonal antibodies market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cancer Monoclonal Antibodies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Antibody Type

  • 6.1 Murine Antibodies
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Chimeric Antibodies
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Humanized Antibodies
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Medication Type

  • 7.1 Bevacizumab (Avastin)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Rituximab (Rituxan)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Trastuzumab (Herceptin)
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Cetuximab (Erbitux)
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Panitumumab (Vectibix)
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Breast Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Blood Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Liver Cancer
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Brain Cancer
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Colorectal Cancer
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by End-User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Research Laboratories
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Others
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amgen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Roche Holding AG
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
    • 14.3.3 AbbVie Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Johnson & Johnson
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Eli Lilly and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Merck & Co. Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Genmab A/S
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 GlaxoSmithKline Plc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Bristol-Myers Squibb Company
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Novartis AG
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Spectrum Pharmaceuticals Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Seattle Genetics Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis
    • 14.3.13 Pfizer Inc.
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Cancer Monoclonal Antibodies Market: Major Drivers and Challenges
  • Figure 2: Global: Cancer Monoclonal Antibodies Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Cancer Monoclonal Antibodies Market: Breakup by Antibody Type (in %), 2023
  • Figure 4: Global: Cancer Monoclonal Antibodies Market: Breakup by Medication Type (in %), 2023
  • Figure 5: Global: Cancer Monoclonal Antibodies Market: Breakup by Application (in %), 2023
  • Figure 6: Global: Cancer Monoclonal Antibodies Market: Breakup by End-User (in %), 2023
  • Figure 7: Global: Cancer Monoclonal Antibodies Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 9: Global: Cancer Monoclonal Antibodies (Murine Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Cancer Monoclonal Antibodies (Murine Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Cancer Monoclonal Antibodies (Chimeric Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Cancer Monoclonal Antibodies (Chimeric Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Cancer Monoclonal Antibodies (Humanized Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Cancer Monoclonal Antibodies (Humanized Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Cancer Monoclonal Antibodies (Other Types of Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Cancer Monoclonal Antibodies (Other Types of Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Cancer Monoclonal Antibodies (Bevacizumab) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Cancer Monoclonal Antibodies (Bevacizumab) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Cancer Monoclonal Antibodies (Rituximab) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Cancer Monoclonal Antibodies (Rituximab) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Cancer Monoclonal Antibodies (Trastuzumab) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Cancer Monoclonal Antibodies (Trastuzumab) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Cancer Monoclonal Antibodies (Cetuximab) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Cancer Monoclonal Antibodies (Cetuximab) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Cancer Monoclonal Antibodies (Panitumumab) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Cancer Monoclonal Antibodies (Panitumumab) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Cancer Monoclonal Antibodies (Other Medication Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Cancer Monoclonal Antibodies (Other Medication Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Cancer Monoclonal Antibodies (Breast Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Cancer Monoclonal Antibodies (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Cancer Monoclonal Antibodies (Blood Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Cancer Monoclonal Antibodies (Blood Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Cancer Monoclonal Antibodies (Liver Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Cancer Monoclonal Antibodies (Liver Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Cancer Monoclonal Antibodies (Brain Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Cancer Monoclonal Antibodies (Brain Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Cancer Monoclonal Antibodies (Colorectal Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Cancer Monoclonal Antibodies (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Global: Cancer Monoclonal Antibodies (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Global: Cancer Monoclonal Antibodies (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Global: Cancer Monoclonal Antibodies (Hospitals and Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Global: Cancer Monoclonal Antibodies (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Global: Cancer Monoclonal Antibodies (Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Global: Cancer Monoclonal Antibodies (Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Global: Cancer Monoclonal Antibodies (Research Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Global: Cancer Monoclonal Antibodies (Research Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Global: Cancer Monoclonal Antibodies (Others) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Global: Cancer Monoclonal Antibodies (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: North America: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: North America: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: United States: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: United States: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Canada: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Canada: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Asia Pacific: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Asia Pacific: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: China: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: China: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Japan: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Japan: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: India: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: India: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: South Korea: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: South Korea: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Australia: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Australia: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Others: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Others: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Europe: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Europe: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Germany: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Germany: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: France: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: France: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: United Kingdom: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: United Kingdom: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Italy: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Italy: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Spain: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Spain: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Russia: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Russia: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Others: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Others: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Latin America: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Latin America: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Brazil: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 88: Brazil: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 89: Mexico: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 90: Mexico: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 91: Others: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 92: Others: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 93: Middle East and Africa: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 94: Middle East and Africa: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 95: Global: Cancer Monoclonal Antibodies Industry: SWOT Analysis
  • Figure 96: Global: Cancer Monoclonal Antibodies Industry: Value Chain Analysis
  • Figure 97: Global: Cancer Monoclonal Antibodies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cancer Monoclonal Antibodies Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Antibody Type (in Million US$), 2024-2032
  • Table 3: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Medication Type (in Million US$), 2024-2032
  • Table 4: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by End-User (in Million US$), 2024-2032
  • Table 6: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Cancer Monoclonal Antibodies Market: Competitive Structure
  • Table 8: Global: Cancer Monoclonal Antibodies Market: Key Players